KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of “Buy” by Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been given an average rating of “Buy” by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $24.83.

Several research firms have recently weighed in on KALV. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Jones Trading reaffirmed a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 5,104 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the completion of the transaction, the chief executive officer now owns 278,855 shares in the company, valued at $2,738,356.10. This represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the stock in a transaction dated Wednesday, April 9th. The shares were bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the transaction, the insider now directly owns 5,303,985 shares of the company’s stock, valued at $49,963,538.70. This represents a 0.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 17,292 shares of company stock valued at $184,625. 10.50% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of KALV. Barclays PLC raised its position in KalVista Pharmaceuticals by 418.5% in the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after buying an additional 54,257 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of KalVista Pharmaceuticals by 8.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $634,000. SG Americas Securities LLC lifted its position in shares of KalVista Pharmaceuticals by 10.0% in the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares in the last quarter.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $11.66 on Friday. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The firm has a fifty day moving average price of $12.03 and a two-hundred day moving average price of $10.42. The firm has a market cap of $579.69 million, a price-to-earnings ratio of -3.20 and a beta of 0.05.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).